CN100509045C - Mongolian medicine for treating coronary heart disease - Google Patents
Mongolian medicine for treating coronary heart disease Download PDFInfo
- Publication number
- CN100509045C CN100509045C CNB2007100635851A CN200710063585A CN100509045C CN 100509045 C CN100509045 C CN 100509045C CN B2007100635851 A CNB2007100635851 A CN B2007100635851A CN 200710063585 A CN200710063585 A CN 200710063585A CN 100509045 C CN100509045 C CN 100509045C
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- radix
- mongolian medicine
- heart disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 25
- 240000000513 Santalum album Species 0.000 claims abstract description 6
- 235000008632 Santalum album Nutrition 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 210000000582 semen Anatomy 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 9
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 7
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 6
- 241000180649 Panax notoginseng Species 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 241000628997 Flos Species 0.000 claims description 5
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000004087 circulation Effects 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 241001346334 Amomum tsao-ko Species 0.000 claims description 2
- 241000510609 Ferula Species 0.000 claims description 2
- 241000498779 Myristica Species 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 1
- 210000002216 heart Anatomy 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 4
- 206010002388 Angina unstable Diseases 0.000 abstract description 2
- 206010003225 Arteriospasm coronary Diseases 0.000 abstract description 2
- 208000007814 Unstable Angina Diseases 0.000 abstract description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 abstract description 2
- 208000010125 myocardial infarction Diseases 0.000 abstract description 2
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 abstract 1
- 244000124209 Crocus sativus Species 0.000 abstract 1
- 235000015655 Crocus sativus Nutrition 0.000 abstract 1
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 235000007162 Ferula assa foetida Nutrition 0.000 abstract 1
- 244000228957 Ferula foetida Species 0.000 abstract 1
- 235000012850 Ferula foetida Nutrition 0.000 abstract 1
- 244000116484 Inula helenium Species 0.000 abstract 1
- 235000002598 Inula helenium Nutrition 0.000 abstract 1
- 241001071917 Lithospermum Species 0.000 abstract 1
- 235000019510 Long pepper Nutrition 0.000 abstract 1
- 244000270834 Myristica fragrans Species 0.000 abstract 1
- 235000009421 Myristica fragrans Nutrition 0.000 abstract 1
- 241000123069 Ocyurus chrysurus Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 240000003455 Piper longum Species 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 244000223014 Syzygium aromaticum Species 0.000 abstract 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 abstract 1
- 235000015278 beef Nutrition 0.000 abstract 1
- 229910052602 gypsum Inorganic materials 0.000 abstract 1
- 239000010440 gypsum Substances 0.000 abstract 1
- 239000001702 nutmeg Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 16
- 210000002784 stomach Anatomy 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 239000000341 volatile oil Substances 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000010792 warming Methods 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 231100000111 LD50 Toxicity 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229930183118 Tanshinone Natural products 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000001306 (7E,9E,11E,13E)-pentadeca-7,9,11,13-tetraen-1-ol Substances 0.000 description 2
- UJQGVDNQDFTTLZ-VNHYZAJKSA-N 2-[(2r,4ar,8as)-4a-methyl-8-methylidene-1,2,3,4,5,6,7,8a-octahydronaphthalen-2-yl]prop-2-enoic acid Chemical compound C1CCC(=C)[C@@H]2C[C@H](C(=C)C(O)=O)CC[C@]21C UJQGVDNQDFTTLZ-VNHYZAJKSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- AKGGYBADQZYZPD-UHFFFAOYSA-N benzylacetone Chemical compound CC(=O)CCC1=CC=CC=C1 AKGGYBADQZYZPD-UHFFFAOYSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930182486 flavonoid glycoside Natural products 0.000 description 2
- 150000007955 flavonoid glycosides Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- DZVXRFMREAADPP-JXUBOQSCSA-N (1s,3s,4s,5r)-4-methyl-1-propan-2-ylbicyclo[3.1.0]hexan-3-ol Chemical compound C([C@H](O)[C@H]1C)[C@@]2(C(C)C)[C@@H]1C2 DZVXRFMREAADPP-JXUBOQSCSA-N 0.000 description 1
- WEFHSZAZNMEWKJ-KEDVMYETSA-N (6Z,8E)-undeca-6,8,10-trien-2-one (6E,8E)-undeca-6,8,10-trien-2-one (6Z,8E)-undeca-6,8,10-trien-3-one (6E,8E)-undeca-6,8,10-trien-3-one (6Z,8E)-undeca-6,8,10-trien-4-one (6E,8E)-undeca-6,8,10-trien-4-one Chemical compound CCCC(=O)C\C=C\C=C\C=C.CCCC(=O)C\C=C/C=C/C=C.CCC(=O)CC\C=C\C=C\C=C.CCC(=O)CC\C=C/C=C/C=C.CC(=O)CCC\C=C\C=C\C=C.CC(=O)CCC\C=C/C=C/C=C WEFHSZAZNMEWKJ-KEDVMYETSA-N 0.000 description 1
- QXRKIZKJLNNMNC-UHFFFAOYSA-N 11,13-Dihydrocostic acid Natural products CC(C1CCC2(C)CCCC(=C)C2C1)C(=O)O QXRKIZKJLNNMNC-UHFFFAOYSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- FKWGZOFNSIESOX-QLFBSQMISA-N 2-[(2r,4ar,8as)-4a-methyl-8-methylidene-1,2,3,4,5,6,7,8a-octahydronaphthalen-2-yl]prop-2-en-1-ol Chemical compound C1CCC(=C)[C@@H]2C[C@H](C(=C)CO)CC[C@]21C FKWGZOFNSIESOX-QLFBSQMISA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- GLZOMALSMBXHLS-UHFFFAOYSA-N COC(C(C)=O)(CC1=CC=CC=C1)CC1=CC=CC=C1 Chemical compound COC(C(C)=O)(CC1=CC=CC=C1)CC1=CC=CC=C1 GLZOMALSMBXHLS-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 description 1
- 241000208809 Carthamus Species 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 1
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000116713 Ferula gummosa Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- PDEQKAVEYSOLJX-UHFFFAOYSA-N Hexahydronerolidol Natural products C1C2C3(C)C2CC1C3(C)CCC=C(CO)C PDEQKAVEYSOLJX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- SGZOYHLQNUSAIL-UHFFFAOYSA-N Ioscostussaeure Natural products C1C(C(=C)C(O)=O)CCC2(C)CCCC(C)=C21 SGZOYHLQNUSAIL-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- ALHUZKCOMYUFRB-OAHLLOKOSA-N Muscone Chemical compound C[C@@H]1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-OAHLLOKOSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 229930190125 Sanguisorbin Natural products 0.000 description 1
- 244000272264 Saussurea lappa Species 0.000 description 1
- 235000006784 Saussurea lappa Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000303379 Styrax officinalis Species 0.000 description 1
- 235000001361 Styrax officinalis Nutrition 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- WNFXUXZJJKTDOZ-HNNXBMFYSA-N [(1s)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] acetate Chemical compound C1=CC(O)=C2C(=O)C([C@@H](OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-HNNXBMFYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- PDEQKAVEYSOLJX-AIEDFZFUSA-N alpha-Santalol Natural products CC(=CCC[C@@]1(C)[C@H]2C[C@@H]3[C@H](C2)[C@]13C)CO PDEQKAVEYSOLJX-AIEDFZFUSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- PDEQKAVEYSOLJX-BKKZDLJQSA-N alpha-santalol Chemical compound C1C2[C@]3(C)C2C[C@H]1[C@@]3(C)CC/C=C(CO)/C PDEQKAVEYSOLJX-BKKZDLJQSA-N 0.000 description 1
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- UTXMCYDEIZPGME-UHFFFAOYSA-N beta-Isocostic acid Natural products C1CC(C(=C)C(O)=O)CC2C(C)=CCCC21C UTXMCYDEIZPGME-UHFFFAOYSA-N 0.000 description 1
- OJYKYCDSGQGTRJ-INLOORNJSA-N beta-Santalol Natural products C1C[C@H]2C(=C)[C@](CC\C=C(CO)/C)(C)[C@@H]1C2 OJYKYCDSGQGTRJ-INLOORNJSA-N 0.000 description 1
- UJQGVDNQDFTTLZ-UHFFFAOYSA-N beta-costic acid Natural products C1CCC(=C)C2CC(C(=C)C(O)=O)CCC21C UJQGVDNQDFTTLZ-UHFFFAOYSA-N 0.000 description 1
- OJYKYCDSGQGTRJ-GQYWAMEOSA-N beta-santalol Chemical compound C1C[C@H]2C(=C)[C@@](CC/C=C(CO)/C)(C)[C@@H]1C2 OJYKYCDSGQGTRJ-GQYWAMEOSA-N 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229930016889 costol Natural products 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000004864 galbanum Substances 0.000 description 1
- ITRHZWKEZJYJQO-UHFFFAOYSA-N gamma-costol Natural products C1C(C(=C)CO)CCC2(C)CCCC(C)=C21 ITRHZWKEZJYJQO-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002608 intravascular ultrasound Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000013147 laser angioplasty Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- ALHUZKCOMYUFRB-UHFFFAOYSA-N muskone Natural products CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 150000008427 organic disulfides Chemical class 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 1
- 229940075559 piperine Drugs 0.000 description 1
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 1
- 235000019100 piperine Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- WNFXUXZJJKTDOZ-UHFFFAOYSA-N shikonin acetate Natural products C1=CC(O)=C2C(=O)C(C(OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-UHFFFAOYSA-N 0.000 description 1
- 230000004905 short-term response Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000036228 toxication Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine, in particular to a Mongolian medicine for treating coronary heart disease, which is called Xintekang clinically. The Mongolian medicine is prepared from the following raw material medicines in parts by weight: 20-70 parts of salvia miltiorrhiza, 10-60 parts of fructus choerospondiatis, 10-50 parts of agilawood, 30-60 parts of pseudo-ginseng, 10-50 parts of saffron crocus, 10-50 parts of nutmeg, 20-60 parts of white sandalwood, 20-60 parts of clove, 40-80 parts of long pepper, 10-60 parts of platycladi seed, 10-50 parts of elecampane, 10-40 parts of Caiyang, 10-40 parts of gypsum, 10-40 parts of asafetida, 10-50 parts of lithospermum, 5-30 parts of madder, 10-40 parts of rhizoma polygonati, 5-30 parts of fructus amomi, 20-100 parts of beef heart and 2-20 parts of musk. Can improve myocardial ischemia of unstable angina patients, relieve coronary spasm, relieve clinical symptoms, prevent myocardial infarction, and has satisfactory curative effect on coronary heart disease.
Description
Technical field the present invention relates to a kind of medicine, promptly a kind of mongolian medicine for the treatment of coronary heart disease.
Background technology coronary heart disease is coronary atherosclerotic heart disease, is a kind of sickness rate height, and is dangerous strong, the cardiovascular disease that mortality rate is high.In many countries and regions, coronary heart disease has become the first cause of death, is known as first killer.In recent years, the Incidence of CHD of China is in rising trend, and the patient is nearly millions of, and shows age of onset and become younger, and the sign that rises of sudden death rate.Therefore, the prevention of coronary heart disease and treatment should cause the attention that we are enough.At present, the coronary heart disease diagnosis technology can satisfy clinical needs, still, and the requirement that the treatment of coronary heart disease also far can not adapt to the situation.Drug therapy, interventional therapy and operative treatment are mainly adopted in the treatment of coronary heart disease.The method of its interventional therapy has stent endoprosthesis, laser angioplasty, Intimectomy, intravascular ultrasound angioplasty etc.Wherein, to insert be the feasible method of comparative maturity to support.Stent endoprosthesis is foley's tube to be driven in the wrong direction for sending into narrow positions coronarius, and the pressurization dilating sacculus enlarges vessel diameter, inserts support again, thereby guarantees the unimpeded of blood.Operative treatment mainly is to carry out the repairing of blood vessel or change its course.Although get involved and the method curative effect of operation is reliably,, because its expense costliness, risk is bigger, and quite a few patient also do not tackle the problem at its root, and exists the hidden danger of other position recurrence, so Most patients is beyond affordability.According to statistics, patient's less than 30,000 people of interventional therapy are carried out in the whole nation every year, and operative treatment still less.As seen, most patients are still by Drug therapy.The medicine of clinical practice at present is a lot, for example nitrate esters, beta receptor blocker, calcium antagonist, coronary dilation agent, anti-platelet aggregation agent, and the medicine of various analgesia, calmness, thrombolytic, blood pressure lowering.The Radix Salviae Miltiorrhizae Tabellae of Chinese medicine, storax pill for treating coronary heart disease etc. also have certain curative effect.Mongolian medicine's pharmacy has its original understanding and special Therapeutic Method for coronary heart disease, is good at pharmacotherapy especially.It is evil in and conspicuous the silt class disease that stagnates that traditional Mongolian medicine thinks that the coronary heart disease symptom in the present age belongs to the heat in blood poison, its performance is that blood is contained malicious amassing, root then is due to the imbalance of general, thereby should take comprehensive treatment measure, and used medicine is not single nourishing blood and promoting blood circulation, more pay attention to removing heat from blood, remove long-pending, pathogenic fire purging, toxin expelling, pay attention to the digestion and metabolism function of the intestines and stomach liver spleen, mongolian medicine dosage is less in addition, and mostly is whole the pulverizing and is used as medicine, it is fast often to have short-term response, the characteristics that long-term effect is good., improve owing to lack to sum up, many mongolian medicine prescriptions are not generalizable, even lost.
Summary of the invention the objective of the invention is on the basis of the Therapeutic Method of compiling the relevant coronary heart disease of Mongolian medicine's mongolian medicine, through experiment screening, provides a kind of mongolian medicine that coronary heart disease is had significant curative effect.
Above-mentioned purpose is realized by following technical scheme: develop a kind of mongolian medicine for the treatment of coronary heart disease, the weight proportion of its raw material is: 20-70 parts of Radix Salviae Miltiorrhizaes, 10-60 parts of Fructus Choerospondiatis, 10-50 parts of Lignum Aquilariae Resinatum, 30-60 parts of Radix Notoginseng, 10-50 parts of Stigma Crocis, 10-50 parts of Semen Myristicaes, 20-60 parts of Santalum albums, 20-60 parts of Flos Caryophyllis, 40-80 parts of Fructus Piperis Longi, 10-60 parts of Semen Platycladi, 10-50 parts of the Radix Aucklandiae, 10-40 parts of Resina Liquidambariss, 10-40 parts in Gypsum Fibrosum, 10-40 parts of Resina Ferulaes, 10-50 parts of Radix Arnebiae (Radix Lithospermi)s, 5-30 parts in Radix Rubiae, 10-40 parts of Rhizoma Polygonatis, 5-30 parts of Fructus Tsaokos, 20-100 parts of Cor Bovis seu Bubali, 2-20 parts in Moschus.
The above-mentioned raw materials medicine mix is stirred, pulverize and be fine powder, make the watered pill.
The mongolian medicine that adopts technique scheme to make is called the special health of heart I number in clinical experiment, can improve unstable angina patient myocardial ischemia through experimental results demonstrate, remove coronary spasm, alleviate clinical symptoms, the generation of prevention heart infarction has satisfied curative effect to coronary heart disease.
Introduce an embodiment and experiment situation below the specific embodiment.
Embodiment: choose following bulk drugs: Radix Salviae Miltiorrhizae 40g, Fructus Choerospondiatis 35g, Lignum Aquilariae Resinatum 25g, Radix Notoginseng 45g by standard, Stigma Croci 30g, Semen Myristicae 25g, Santalum album 35g, Flos Caryophylli 50g, Fructus Piperis Longi 55g, Semen Platycladi 45g, Radix Aucklandiae 25g, Resina Liquidambaris 25g, Gypsum Fibrosum 20g, Resina Ferulae 25g, Radix Arnebiae (Radix Lithospermi) 20g, Radix Rubiae 15g, Rhizoma Polygonati 15g, Fructus Tsaoko 15g, Cor Bovis seu Bubali 40g, Moschus 5g.
After above-mentioned raw materials mix stirred, be crushed to 120 orders, get the watered pill with watered pill machine by high speed wind-suction type pulverizer, usefulness hot air circulation medicine drying machine drying, and with the Cinnabaris coating of 10-50g.
5 heavy 1g of the watered pill, the each oral 3-6g of adult, every day 2-3 times, 20 is a course of treatment.
The experiment situation:
One. toxicity test
1. anxious poison test.According to the pertinent regulations of study of tcm new drug, to the median lethal dose(LD 50) (LD of mouse stomach administration
50) carried out test determination, but do not measure LD
50, therefore carried out mtd test.Result: with Cmax (60%), maximum dosage-feeding (120ml/kg, dividing in one day and give for four times) 100g/Kg irritates stomach, be equivalent to crude drug amount 60g/kg, be equivalent to be grown up 200 times of the daily dosage of clinical plan (press 60kg, 0.3g/kg), none death of mice in seven days, put to death each internal organs of mice anatomic observation and do not find toxic reaction, administration group and control group mice do not have any difference.
2. long term toxication.For clinical drug safety, according to the pertinent regulations of country to new drug research, application Wistar rat will be tested medicine and will be set at high, medium and low three dosage, be respectively watered pill granule 24g/kg, 12g/kg, 6g/kg.Press 0.3g/kg/ days granules of human dosage and calculate, be 80 times, 40 times and 20 times of human effective dose; Other establishes a matched group, and gastric infusion is 90 days, 180 days continuously, and the drug withdrawal of part animal was observed the influence to the every physiology of rat, biochemical indicator after 10 days.Experimental result shows: gave the rat continuous oral 180 days with various dose, food-intake and the body weight gain of rat all do not had influence.Hepatic and renal function is not all found the overt toxicity effect.Routine blood test, blood biochemistry, urine biochemistry and bone marrow sheet etc. be there is no obvious influence, compare no significant difference with matched group between each group.
Two. clinical experiment
Since 2002, in patients with coronary heart disease 64 examples of medical institutions' picked at random such as Tongliao, Inner Mongolia city spy health difficult disease institutes by making a definite diagnosis, be divided into experimental group and matched group at random, every group 32 example, experimental group adopts I number treatment of the special health of the heart, matched group adopts routine medication, the situation of change of paired observation two groups of cardinal symptoms, sign and every physiochemical indices, experimental data is learned by statistics to handle and is found, the matched group (P＜0.01) that is better than evident in efficacy of experimental group, particularly the index variation at blood pressure, blood fat, blood glucose obviously are better than matched group (P＜0.05).
Pharmacology analysis: traditional Mongolian medicine is classified as coronary heart disease burning hot evil sick, and is corresponding with the qi depression to blood stasis of the traditional Chinese medical science, how to reduce internal heat except that evil to fall heat in treatment, and regulating the flow of vital energy nourishes blood is principle, simultaneously, carries out whole Comprehensive Treatment, and Radix Salviae Miltiorrhizae contains TANSHINONES first (C
18H
12O
3), TANSHINONES second (C
19H
18O
3), the TANSHINONES third (C
19H
20O
3), cryptotanshinone (C
19H
20O
3), VE etc., can go into the heart, Liver Channel, have blood circulation promoting and blood stasis dispelling, clearing heat and relieving fidgetness, blood vessel dilating and blood pressure lowering, antibiotic, calmness is calmed the nerves, effects such as analgesia have definite curative effect to the angina pectoris due to the retardance of heart arteries and veins, myocardial infarction, deficiency of heart-blood etc.Fructus Choerospondiatis is the dry fruit of Anacardiaceae plant Fructus Choerospondiatis, is the conventional crude drugs of mongolian medicine, and Mongolian claims pearl as Chinese herbaceous peony sand very, contain compositions such as Fructus Choerospondiatis total flavones, Fructus Choerospondiatis flavone, Fructus Choerospondiatis polysaccharide, nature and flavor acid, sweet, flat, greasy, heavy, gentle, document records clearing away heart-fire, improve the effect of cardiac function, be used for the breast twinge more, coma, demented, angina pectoris, pain heart failure uncomfortable in chest, the heart is conspicuous according to disease etc., and the frequency that occurs in the mongolian medicine proved recipe is higher.Lignum Aquilariae Resinatum contains volatile oil and resin, contains benzylacetone in the oil, to methoxybenzyl benzylacetone, senior terpene alcohol etc., goes into stomach, kidney, spleen channel, but sending down the abnormal ascending QI, warming middle-JIAO, warming the kidney is supporing yang, the merit of mainly get its sending down the abnormal ascending QI among the we, regulating the flow of vital energy.Radix Notoginseng contains arasaponin first (C
30H
22O
16), arasaponin second (C
22H
33O
15) and flavonoid glycoside, go into liver, stomach warp, hemostasia and dissipation blood stasis, anti-inflammation, reducing swelling and alleviating pain are arranged, its Radix Notoginseng flavonoid glycoside can obviously increase the heart coronary artery flow, reduces myocardial oxygen consumption simultaneously.Stigma Croci contains carthamin (C
21H
22O
11), Carthamus yellow (C
24H
30O
5), can break becomes silted up invigorates blood circulation, and blood pressure lowering, expansion blood vessel are outstanding with heat-clearing and toxic substances removing effectiveness especially.Semen Myristicae contains dextrorotation camphene and α pinene vinyl volatile oil, fat, Fructus Amomi Rotundus ether (C
11H
12O
3) etc., go into spleen, stomach, large intestine channel, but warming the middle warmer and descending qi, astringent or styptic treatment for spontaneous sweating convergence.Santalum album contains volatile oil, is mainly α-and β-santalol (C
15H
24O) go into spleen, stomach warp, but regulating QI to relieve pain.Flos Caryophylli contains eugenol (C
10H
12O
2), tannin, oleanolic acid etc., go into spleen, stomach, kidney, lung meridian, but sun falls in warming middle-JIAO, therapeutic method to keep the adverse QI flowing downwards sending down the abnormal ascending QI, the wind dispelling that is good for the stomach, antibiotic, antiviral, antifungal.Fructus Piperis Longi contains piperine and volatile oil, goes into stomach, large intestine channel, but warming spleen and stomach for dispelling cold, wind dispelling pain relieving, the soothing the liver therapeutic method to keep the adverse QI flowing downwards.Semen Platycladi contains fatty oils such as thujol, Borneolum Syntheticum fat.Go into the heart, spleen channel, but reinforcing the heart god, moistening dryness for relaxing bowels.The Radix Aucklandiae contains constuslactone (C
15H
20O
2), costic acid (C
15H
22O
2), costol (C
15H
24O), α-and β-costene (C
15H
24) wait volatile oil, and Saussurea lappa Clarke alkali, resin, inulin, go into spleen, large intestine, tri-jiao channel, have effects such as circulation of qi promoting, pain relieving, digestion-promoting spleen-invigorating.Resina Liquidambaris 25g, Gypsum Fibrosum are calcium sulfate, go into lung, stomach, tri-jiao channel, but resolving heat and reducing pathogenic fire, the relieving restlessness of quenching the thirst.Resina Ferulae contains pinene and organic disulfide class volatile oil, and the galbanum phenol etc. of tanning, and goes into spleen, stomach warp, and the painful abdominal mass but removing food stagnancy looses is removed chest and abdomen swelling and pain, suppresses tumor.Radix Arnebiae (Radix Lithospermi) contains acetylshikonin (C
18H
18O
6), go into the heart, Liver Channel, the effect of heart tonifying, analgesic, detoxifcation, rash, antibiotic, antiviral, antifungal is arranged.Radix Rubiae contains catechu tanninoids, sanguisorbin VA etc., goes into liver, kidney, large intestine channel, but clearing away heat and cooling blood, hemostasia and detumescence, anti-inflammation.Rhizoma Polygonati contains biological alkali, starch, sugar etc., goes into spleen, lung, stomach warp, effect such as have healthcare, promoting the production of body fluid to quench thirst, inhibiting bacteria and diminishing inflammation, bring high blood pressure down.Fructus Tsaoko contains volatile oil, goes into spleen, stomach warp, but cold expelling dampness, the expectorant preventing the attack (or recurrence) of malaria.Cor Bovis seu Bubali is the special-purpose medicine of Mongolian medicine, and promptly the dry product of the heart of cattle has the effect that reinforcing the heart is nourished blood.The artificial Moschus contains muscone (C
16H
30O), go into the heart, spleen, Liver Channel, can have one's ideas straightened out that it is dirty to ward off, blood circulation promoting and dispersing pathogen accumulation, antibiotic disappear sticking.From the effect meridians of said medicine, be based on heart channel, be aided with meridians such as liver, lung, spleen, stomach, intestinal, both given prominence to emphasis, considered composite factor again.From the property of medicine, adopted based on nourishing blood and promoting blood circulation, regulating the flow of QI to dissipate blood stasis, with build spleen, promote the production of body fluid, heat clearing away, detoxifcation, sticking, the bactericide of disappearing is auxilliary, given prominence to removing food stagnancy, change expand, have one's ideas straightened out, the pharmacological action of eliminating stagnation.On usage, adopt to be ground into ball, decoct without high temperature, can keep the efficacy of a drug to greatest extent, in addition with the Cinnabaris coating, more can receive calmness, take shelter, heat clearing away, antidotal effect.The more important thing is that the various kinds of drug ratio is proper, the principal and subordinate is orderly, and each shows its merit and complements each other, and makes disease obtain basic treatment.
Claims (4)
1. mongolian medicine for the treatment of coronary heart disease, it is characterized in that: this mongolian medicine is made by following materials of weight proportions medicine: 20-70 parts of Radix Salviae Miltiorrhizaes, 10-60 parts of Fructus Choerospondiatis, 10-50 parts of Lignum Aquilariae Resinatum, 30-60 parts of Radix Notoginseng, 10-50 parts of Stigma Crocis, 10-50 parts of Semen Myristicaes, 20-60 parts of Santalum albums, 20-60 parts of Flos Caryophyllis, 40-80 parts of Fructus Piperis Longi, 10-60 parts of Semen Platycladi, 10-50 parts of the Radix Aucklandiae, 10-40 parts of Resina Liquidambariss, 10-40 parts in Gypsum Fibrosum, 10-40 parts of Resina Ferulaes, 10-50 parts of Radix Arnebiae (Radix Lithospermi)s, 5-30 parts in Radix Rubiae, 10-40 parts of Rhizoma Polygonatis, 5-30 parts of Fructus Tsaokos, 20-100 parts of Cor Bovis seu Bubali, 2-20 parts in Moschus.
2. mongolian medicine for the treatment of coronary heart disease, it is characterized in that: this mongolian medicine is made by following materials of weight proportions medicine: Radix Salviae Miltiorrhizae 40g, Fructus Choerospondiatis 35g, Lignum Aquilariae Resinatum 25g, Radix Notoginseng 45g, Stigma Croci 30g, Semen Myristicae 25g, Santalum album 35g, Flos Caryophylli 50g, Fructus Piperis Longi 55g, Semen Platycladi 45g, Radix Aucklandiae 25g, Resina Liquidambaris 25g, Gypsum Fibrosum 20g, Resina Ferulae 25g, Radix Arnebiae (Radix Lithospermi) 20g, Radix Rubiae 15g, Rhizoma Polygonati 15g, Fructus Tsaoko 15g, Cor Bovis seu Bubali 40g, Moschus 5g.
3. the mongolian medicine of treatment coronary heart disease according to claim 1 is characterized in that: the manufacture method of this mongolian medicine is: the above-mentioned raw materials medicine mix is stirred, pulverize and be fine powder, make the watered pill.
4. the mongolian medicine of treatment coronary heart disease according to claim 1, it is characterized in that: the manufacture method of this mongolian medicine is: after said raw material is mixed stirring, be crushed to 120 orders by high speed wind-suction type pulverizer, get the watered pill with watered pill machine, with hot air circulation medicine drying machine drying, and with the Cinnabaris coating of 10-50g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100635851A CN100509045C (en) | 2007-02-05 | 2007-02-05 | Mongolian medicine for treating coronary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100635851A CN100509045C (en) | 2007-02-05 | 2007-02-05 | Mongolian medicine for treating coronary heart disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101011551A CN101011551A (en) | 2007-08-08 |
| CN100509045C true CN100509045C (en) | 2009-07-08 |
Family
ID=38699391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2007100635851A Expired - Fee Related CN100509045C (en) | 2007-02-05 | 2007-02-05 | Mongolian medicine for treating coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100509045C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103656446B (en) * | 2013-03-25 | 2017-05-31 | 内蒙古医科大学 | Treat the compound Mongolian medicinal preparation and its preparation technology of coronary heart disease |
| CN103142923B (en) * | 2013-03-25 | 2015-01-28 | 内蒙古医科大学 | Compound mongolian medicine preparation for treating coronary heart disease |
| CN104137938A (en) * | 2014-08-26 | 2014-11-12 | 哈尔滨灵丹鸿运茶品有限公司 | Fructus trichosanthis root tea capable of relieving chest stuffiness and reducing mass and production method thereof |
| CN104958712A (en) * | 2015-07-29 | 2015-10-07 | 张琳 | Composition preparation for preventing and treating coronarospasm and preparation method thereof |
| CN106214854A (en) * | 2016-08-30 | 2016-12-14 | 肃北蒙古族自治县蒙医医院 | A kind of medicine treating cardiovascular disease |
| CN111643623B (en) * | 2020-06-12 | 2022-01-04 | 纳顺达来 | Mongolian medicine for treating coronary heart disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1840147A (en) * | 2006-01-03 | 2006-10-04 | 吴坚 | Tibet medicine for resisting virus, eliminating inflammation and expelling toxin |
-
2007
- 2007-02-05 CN CNB2007100635851A patent/CN100509045C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1840147A (en) * | 2006-01-03 | 2006-10-04 | 吴坚 | Tibet medicine for resisting virus, eliminating inflammation and expelling toxin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101011551A (en) | 2007-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100509045C (en) | Mongolian medicine for treating coronary heart disease | |
| CN105497620A (en) | Health-care traditional Chinese medicine preparation for weight reduction and body building | |
| CN103169793A (en) | Medicine for treating hypertension, hyperlipoidemia and diabetes mellitus | |
| CN118105451A (en) | Medicinal and edible composition for preventing and treating ulcerative colitis and application thereof | |
| CN1306951C (en) | Medicine for curing qi deficiency induced thoracic obstruction (coronary heart disease) and technique for preparing the same | |
| CN101537160B (en) | Health product for toxicant elimination and beauty maintenance | |
| CN103933450A (en) | Traditional Chinese medicine composition for preventing or/and treating gastrointestinal diseases and preparation method of composition | |
| CN103599455B (en) | Traditional Chinese medicine capsule for removing freckle | |
| CN102886019A (en) | Traditional Chinese medicinal blood sugar reducing plaster | |
| CN102343049B (en) | Chinese medicinal capsules for treating hypertension due to liver-yang hyperactivity | |
| CN100579544C (en) | Chinese medicament preparation for treating cholecystitis and gall-stone as well as preparation method thereof | |
| CN101214365A (en) | Chinese medicine composing prescription for treating mastoproliferation | |
| CN101015655A (en) | Children's anti-epilepsy agent | |
| CN1990033A (en) | Drug for treating hypertension, dense blood and arteriosclerosis | |
| CN1726964A (en) | Chinese materia medica preparation for curing fracture and traumatic injury | |
| CN105664053A (en) | Traditional Chinese medicine composition for treating calluses on puncture of internal arteriovenous fistula of maintenance hemodialysis patient | |
| CN100348252C (en) | Chinese medicinal product for protecting liver and freezing bowel | |
| CN101129492A (en) | Traditional Chinese medicine formulated product for treating melancholia | |
| CN104800772A (en) | Traditional Chinese medicine composition for treating vital-energy-depression type coronary heart disease and application of traditional Chinese medicine composition | |
| CN104095992A (en) | Composition for strengthening teeth, strengthening muscles and bones, building fitness and resisting aging, and preparation method and application thereof | |
| CN104645152B (en) | A kind of pharmaceutical composition for the treatment of gastric ulcer and preparation method thereof | |
| CN114377063B (en) | Traditional Chinese medicine composition for treating delayed fracture healing | |
| CN106617038A (en) | Health-care food composition for relieving male frequent urination and urinary incontinence as well as preparation method and application of health-care food composition | |
| CN101264268B (en) | Proprietary Chinese medicine for treating tumor | |
| CN1078084C (en) | Medicinal composition for treating psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090708 Termination date: 20180205 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |